DBV Technologies (CHIX:DBVP) Moat Score: 4/10 (As of Jul. 01, 2026)


CHIX:DBVP DBV Technologies SA CHIX:DBVP
31 GF Score
Price €2.91
! 1 Warning Sign
View Full Analysis

What is DBV Technologies Moat Score?

DBV Technologies CHIX:DBVP 31 Moat Score is 4 as of Jul. 01, 2026. GuruFocus rates CHIX:DBVP with a GF Score™ of 31/100. The stock has 1 warning sign investors should review. Among 1,400 Biotechnology companies, DBV Technologies ranks better than 88.79% on this metric.

DBV Technologies has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

DBV Technologies has Narrow Moat: DBV Technologies SA has valuable intellectual property and patents in the biotech sector. However, it faces significant competition and lacks strong brand strength or customer loyalty, limiting its moat to a modest level.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes DBV Technologies might have Narrow Moat - Discernible but modest moat.

DBV Technologies  (CHIX:DBVp) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

DBV Technologies Moat Score Related Terms

CHIX:DBVP vs VRTX, REGN, ALNY: Moat Score Comparison

For the Biotechnology subindustry, DBV Technologies's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

DBV Technologies Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, DBV Technologies's Moat Score distribution charts can be found below:

* The bar in red indicates where DBV Technologies's Moat Score falls into.


CHIX:DBVP
31GF Score
DBV Technologies SA CHIX:DBVP
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
DBV Technologies (CHIX:DBVP) has a Moat Score of 4 as of Jul. 01, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, DBV Technologies ranks #157 out of 1400 companies in the Biotechnology industry, placing it in the top 11.2%.
Is DBV Technologies' Moat Score too high?
DBV Technologies' current Moat Score is 4. The Biotechnology industry median Moat Score is 2.00. DBV Technologies' value of 4 is 100% above this industry median. Based on the distribution chart, DBV Technologies ranks #157 out of 1400 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, DBV Technologies has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does DBV Technologies' Moat Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, DBV Technologies ranks #157 out of 1400 companies for Moat Score. This places DBV Technologies in the top 11% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. DBV Technologies' value of 4 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,400 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DBV Technologies's current Moat Score of 4 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DBV Technologies's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DBV Technologies stock overvalued right now?
DBV Technologies (CHIX:DBVP) has a current Moat Score of 4. The current Moat Score is 4 and 100% above the Biotechnology industry median of 2.00. DBV Technologies' overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For DBV Technologies (CHIX:DBVP), the current Moat Score is 4 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

DBV Technologies Business Description

Address 107 Avenue de la Republique, Batiment IRO, Chatillon, Paris, FRA, 92320
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
31GF Score

Get the complete analysis for CHIX:DBVP

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.91
Price